@misc{549d612d0f00465396901a3122d09a61,
title = "KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer",
abstract = " Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.",
author = "Cutter, {Noelle L}",
note = "By: Noelle Cutter, PhD Posted: Monday, May 3, 2021 Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1-enriched tumors experienced longer progression-free survival with the anti-PD-1 inhibitor.",
year = "2021",
month = may,
day = "3",
language = "American English",
}